Area of research
Rheumatology · Genetics
Research interest
Research interests include Urticaria and Related Conditions, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Drug-Induced Adverse Reactions, and Autoimmune Bullous Skin Diseases.
Remibrutinib in Chronic Spontaneous Urticaria
Diagnostic testing for chronic spontaneous urticaria with or without angioedema: The do's, don't and maybe's
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
Efficacy And Safety Of Bradykinin B2 Receptor Inhibition With Oral PHVS416 In Treating Hereditary Angioedema Attacks: Results Of RAPIDe-1 Phase 2 Trial
A concept for integrated care pathways for atopic dermatitis—A GA<sup>2</sup>LEN ADCARE initiative
Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: Results from the Phase-3 Pivotal Trials
In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one‐year extension study
Ligelizumab for Chronic Spontaneous Urticaria
Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from <scp>ASSURE</scp>‐<scp>CSU</scp>
Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab
The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from <scp>ASSURE</scp>‐<scp>CSU</scp>
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor
Definition, aims, and implementation of <scp>GA</scp><sup>2</sup><scp>LEN</scp> Urticaria Centers of Reference and Excellence
A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria
Controversies and challenges in the management of chronic urticaria
The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
ASSURE‐CSU: a real‐world study of burden of disease in patients with symptomatic chronic spontaneous urticaria
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
Methods report on the development of the 2013 revision and update of the <scp>EAACI</scp>/<scp>GA<sup>2</sup>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> guideline for the definition, classification, diagnosis, and management of urticaria
Canadian hereditary angioedema guideline